CYCN
NASDAQ · Biotechnology
Cyclerion Therapeutics Inc
$31.11
-0.06 (-0.19%)
Financial Highlights (FY 2026)
Revenue
33.04M
Net Income
-56,195,672
Gross Margin
—
Profit Margin
-170.1%
Rev Growth
+8.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 39.7% | 39.7% |
| Operating Margin | -176.3% | -158.7% | -12.7% | -11.4% |
| Profit Margin | -170.1% | -161.6% | -11.8% | -14.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 33.04M | 30.49M | 1.11M | 1.23M |
| Gross Profit | — | — | 442.6K | 486.9K |
| Operating Income | -58,234,827 | -48,367,796 | -141,781 | -140,156 |
| Net Income | -56,195,672 | -46,674,146 | -131,808 | -179,754 |
| Gross Margin | — | — | 39.7% | 39.7% |
| Operating Margin | -176.3% | -158.7% | -12.7% | -11.4% |
| Profit Margin | -170.1% | -161.6% | -11.8% | -14.7% |
| Rev Growth | +8.4% | +8.4% | +14.6% | +14.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 868.7K | 867.2K |
| Total Equity | — | — | 1.44M | 1.67M |
| D/E Ratio | — | — | 0.60 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -58,232,518 | -51,052,872 | -161,572 | -173,205 |
| Free Cash Flow | — | — | -153,109 | -131,610 |